Re: Bhide AA et al. Bladder contractility index changes with short-term antimuscarinic therapy in patients with detrusor overactivity: A placebo controlled randomised study

被引：0

作者：

Valdevenito, Juan Pablo ^{[1
]}

Olea, Mauricio ^{[1
]}

Mercado-Campero, Alejandro ^{[1
]}

机构：

[1] Hosp Clin Univ Chile, Dept Urol, Dr Carlos Lorca Tobar 999, Santiago, Chile

来源：

CONTINENCE | 2024年 / 9卷

关键词：

Antimuscarinics; Detrusor contractility; Urodynamics; FLOW;

D O I：

10.1016/j.cont.2023.101064

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

[No abstract available]

引用

页数：2

共 50 条

[31] Re: Christian Gratzke, Rob van Maanen, Christopher Chapple, et al. Long-term Safety and Efficacy of Combined Mirabegron and Solifenacin Compared with Monotherapy in Patients with Overactive Bladder: A Randomised, Multicentre Phase 3 Study (SYNERGY II). Eur Urol 2018;74:501-9
Lee, So-Ryoung
Park, Byoung-Won
Kim, Jae Heon
EUROPEAN UROLOGY, 2019, 75 (03) : E57 - E58
[32] Randomised controlled trial of the short-term effects of osmotic-release oral system methylphenidate on symptoms and behavioural outcomes in young male prisoners with attention deficit hyperactivity disorder (ADHD): CIAO-II study: commentary, Asherson et al
Asherson, Philip
Forrester, Andrew
Johansson, Lena
Thomson, Lindsay
BRITISH JOURNAL OF PSYCHIATRY, 2024, 225 (03) : 412 - 413
[33] Reply to Pascal Mouracade's Letter to the Editor re: Rustom P. Manecksha, Ivor M. Cullen, Sarfraz Ahmad, et al. Prospective Randomised Controlled Trial Comparing Trigone-Sparing versus Trigone-Including Intradetrusor Injection of AbobotulinumtoxinA for Refractory Idiopathic Detrusor Overactivity. Eur Urol 2012;61:928-35
Manecksha, Rustom P.
Cullen, Ivor M.
Ahmad, Sarfraz
McNeill, Graeme
Flynn, Robert
McDermott, Thomas E. D.
Grainger, Ronald
Thornhill, John A.
EUROPEAN UROLOGY, 2012, 61 (05) : E42 - E42
[34] Reply to Claudia Signorini and Massimo Maffezzini's Letter to the Editor re: Maria S. Lindgren, Peter Bue, Nessn Azawi, et al. The DaBlaCa-13 Study: Short-term, Intensive Chemoresection Versus Standard Adjuvant Intravesical Instillations in Non-muscle-invasive Bladder Cancer-A Randomized Controlled Trial. Eur Urol 2020;78:856-62
Lindgren, Maria S.
Jensen, Jorgen B.
EUROPEAN UROLOGY, 2021, 79 (05) : E137 - E137
[35] Re: Claude Schulman, Erik Cornel, Vsevolod Matveev, et al. Intermittent Versus Continuous Androgen Deprivation Therapy in Patients with Relapsing or Locally Advanced Prostate Cancer: A Phase 3b Randomised Study (ICELAND). Eur Urol 2016;69:720-7
Liu, Peihua
Liu, Longfei
Zu, Xiongbing
EUROPEAN UROLOGY, 2017, 71 (02) : E68 - E68
[36] Reply to Manish Garg, Apul Goel and Jai Prakash's Letter to the Editor re: Renzo Colombo, Lorenzo Rocchini, Nazareno Suardi, et al. Neoadjuvant Short-term Intensive Intravesical Mitomycin C Regimen Compared with Weekly Schedule for Low-grade Recurrent Non-muscle-invasive Bladder Cancer: Preliminary Results of a Randomised Phase 2 Study. Eur Urol 2012;62:797-802
Colombo, Renzo
Rocchini, Lorenzo
Suardi, Nazareno
Benigni, Fabio
Colciago, Giorgia
Bettiga, Arianna
Pellucchi, Federico
Maccagnano, Carmen
Briganti, Alberto
Salonia, Andrea
Rigatti, Patrizio
Montorsi, Francesco
EUROPEAN UROLOGY, 2013, 63 (01) : E7 - E8
[37] Re Kessler P et al. Neoadjuvant and adjuvant therapy in patients with oral squamous cell carcinoma. Long-term survival in a prospective, non-randomized study. Br J Oral Maxillofac Surg 2008; 46: 1-5
Brown, Jarnes S.
Shaw, Richard J.
Rogers, Simon N.
Lowe, Derek
BRITISH JOURNAL OF ORAL & MAXILLOFACIAL SURGERY, 2008, 46 (08): : 697 - 697
[38] Re: Robert A. Huddart, Emma Hall, Rebecca Lewis, et al. Patient-reported Quality of Life Outcomes in Patients Treated for Muscle-invasive Bladder Cancer with Radiotherapy Chemotherapy in the BC2001 Phase III Randomised Controlled Trial. Eur Urol 2020;77:260-8
Liu, Wei
Liu, Xiaoping
Li, Shen
EUROPEAN UROLOGY, 2020, 77 (06) : E154 - E155
[39] Re: Wei Shen Tan, Aaron Prendergast, Charlotte Ackerman, et al. Adjuvant Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non-muscle-invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Controlled Trial. Eur Urol. In press.
Sahoo, Suman
Pandey, Abhishek
Mandal, Swarnendu
Das, Manoj Kumar
Nayak, Prasant
EUROPEAN UROLOGY, 2023, 83 (02) : E47 - E47
[40] Re: Wei Shen Tan, Aaron Prendergast, Charlotte Ackermann, et al. Adjuvant Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non-muscle-invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Controlled Trial. Eur Urol. In press.
Campodonico, Fabio
Mattioli, Francesca
Introini, Carlo
EUROPEAN UROLOGY, 2023, 83 (02) : E56 - E57

← 1 2 3 4 5 →